Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 20

1.

Autotaxin Expression Is Regulated at the Post-transcriptional Level by the RNA-binding Proteins HuR and AUF1.

Sun S, Zhang X, Lyu L, Li X, Yao S, Zhang J.

J Biol Chem. 2016 Dec 9;291(50):25823-25836. Epub 2016 Oct 26.

PMID:
27784781
2.

Polyunsaturated lysophosphatidic acid as a potential asthma biomarker.

Ackerman SJ, Park GY, Christman JW, Nyenhuis S, Berdyshev E, Natarajan V.

Biomark Med. 2016;10(2):123-35. doi: 10.2217/bmm.15.93. Epub 2016 Jan 14. Review.

3.

Type I Interferons Function as Autocrine and Paracrine Factors to Induce Autotaxin in Response to TLR Activation.

Song J, Guan M, Zhao Z, Zhang J.

PLoS One. 2015 Aug 27;10(8):e0136629. doi: 10.1371/journal.pone.0136629. eCollection 2015.

4.

Possible role of lysophosphatidic acid in rat model of hypoxic pulmonary vascular remodeling.

Shlyonsky V, Naeije R, Mies F.

Pulm Circ. 2014 Sep;4(3):471-81. doi: 10.1086/677362.

5.

Lysophosphatidic acid receptor 5 inhibits B cell antigen receptor signaling and antibody response.

Hu J, Oda SK, Shotts K, Donovan EE, Strauch P, Pujanauski LM, Victorino F, Al-Shami A, Fujiwara Y, Tigyi G, Oravecz T, Pelanda R, Torres RM.

J Immunol. 2014 Jul 1;193(1):85-95. doi: 10.4049/jimmunol.1300429. Epub 2014 Jun 2.

6.

LPA receptor signaling: pharmacology, physiology, and pathophysiology.

Yung YC, Stoddard NC, Chun J.

J Lipid Res. 2014 Jul;55(7):1192-214. doi: 10.1194/jlr.R046458. Epub 2014 Mar 18.

7.

Lysophospholipid receptor nomenclature review: IUPHAR Review 8.

Kihara Y, Maceyka M, Spiegel S, Chun J.

Br J Pharmacol. 2014 Aug;171(15):3575-94. doi: 10.1111/bph.12678. Epub 2014 Jul 12. Review.

8.

Lysophosphatidic acid inhibits CD8 T cell activation and control of tumor progression.

Oda SK, Strauch P, Fujiwara Y, Al-Shami A, Oravecz T, Tigyi G, Pelanda R, Torres RM.

Cancer Immunol Res. 2013 Oct;1(4):245-55. doi: 10.1158/2326-6066.CIR-13-0043-T.

9.

Autotaxin production of lysophosphatidic acid mediates allergic asthmatic inflammation.

Park GY, Lee YG, Berdyshev E, Nyenhuis S, Du J, Fu P, Gorshkova IA, Li Y, Chung S, Karpurapu M, Deng J, Ranjan R, Xiao L, Jaffe HA, Corbridge SJ, Kelly EA, Jarjour NN, Chun J, Prestwich GD, Kaffe E, Ninou I, Aidinis V, Morris AJ, Smyth SS, Ackerman SJ, Natarajan V, Christman JW.

Am J Respir Crit Care Med. 2013 Oct 15;188(8):928-40. doi: 10.1164/rccm.201306-1014OC.

10.

Plasma proteome analysis reveals overlapping, yet distinct mechanisms of immune activation in chronic HCV and HIV infections.

Schlatzer DM, Sugalski JM, Chen Y, Barnholtz-Sloan J, Davitkov P, Hazlett FE, Funderburg N, Rodriguez B, Lederman MM, Sieg SF, Chance MR, Anthony DD.

J Acquir Immune Defic Syndr. 2013 Aug 15;63(5):563-71. doi: 10.1097/QAI.0b013e3182909847.

11.

Lpa2 is a negative regulator of both dendritic cell activation and murine models of allergic lung inflammation.

Emo J, Meednu N, Chapman TJ, Rezaee F, Balys M, Randall T, Rangasamy T, Georas SN.

J Immunol. 2012 Apr 15;188(8):3784-90. doi: 10.4049/jimmunol.1102956. Epub 2012 Mar 16.

12.
13.

LPA stimulates intestinal DRA gene transcription via LPA2 receptor, PI3K/AKT, and c-Fos-dependent pathway.

Singla A, Kumar A, Priyamvada S, Tahniyath M, Saksena S, Gill RK, Alrefai WA, Dudeja PK.

Am J Physiol Gastrointest Liver Physiol. 2012 Mar 15;302(6):G618-27. doi: 10.1152/ajpgi.00172.2011. Epub 2011 Dec 8.

14.

Regulation of mammalian physiology, development, and disease by the sphingosine 1-phosphate and lysophosphatidic acid receptors.

Blaho VA, Hla T.

Chem Rev. 2011 Oct 12;111(10):6299-320. doi: 10.1021/cr200273u. Epub 2011 Sep 22. Review. No abstract available.

15.

International Union of Basic and Clinical Pharmacology. LXXVIII. Lysophospholipid receptor nomenclature.

Chun J, Hla T, Lynch KR, Spiegel S, Moolenaar WH.

Pharmacol Rev. 2010 Dec;62(4):579-87. doi: 10.1124/pr.110.003111. Review.

16.

Aiming drug discovery at lysophosphatidic acid targets.

Tigyi G.

Br J Pharmacol. 2010 Sep;161(2):241-70. doi: 10.1111/j.1476-5381.2010.00815.x. Review.

17.

Lysophosphatidic acid enhances pulmonary epithelial barrier integrity and protects endotoxin-induced epithelial barrier disruption and lung injury.

He D, Su Y, Usatyuk PV, Spannhake EW, Kogut P, Solway J, Natarajan V, Zhao Y.

J Biol Chem. 2009 Sep 4;284(36):24123-32. doi: 10.1074/jbc.M109.007393. Epub 2009 Jul 8.

18.

Lysophosphatidic acid signaling in airway epithelium: role in airway inflammation and remodeling.

Zhao Y, Natarajan V.

Cell Signal. 2009 Mar;21(3):367-77. doi: 10.1016/j.cellsig.2008.10.010. Epub 2008 Oct 26. Review.

19.

CARMA3 mediates lysophosphatidic acid-stimulated cytokine secretion by bronchial epithelial cells.

Medoff BD, Landry AL, Wittbold KA, Sandall BP, Derby MC, Cao Z, Adams JC, Xavier RJ.

Am J Respir Cell Mol Biol. 2009 Mar;40(3):286-94. doi: 10.1165/rcmb.2008-0129OC. Epub 2008 Aug 28.

20.

Lysophosphatidic acid induces interleukin-13 (IL-13) receptor alpha2 expression and inhibits IL-13 signaling in primary human bronchial epithelial cells.

Zhao Y, He D, Zhao J, Wang L, Leff AR, Spannhake EW, Georas S, Natarajan V.

J Biol Chem. 2007 Apr 6;282(14):10172-9. Epub 2007 Feb 6.

Supplemental Content

Support Center